BioSpace News Archive

On the back of a $135 million public offering in February, rare disease gene therapy company Krystal Biotech has launched subsidiary Jeune Inc. to promote its gene therapies for aesthetic skin conditions.

Virtual meetings might have enhanced the ways we connect with each other but it can be really hard to communicate with someone who doesn’t know the basic Zoom meeting etiquette.

Three days after U.S. Food and Drug Administration staff raised safety concerns over Pfizer’s and Eli Lilly’s NGF osteoarthritis drug tanezumab, an advisory panel has also posted its own objections.

AstraZeneca released primary analysis that the vaccine demonstrated 76% efficacy against symptomatic COVID-19, 100% efficacy against severe or critical disease and hospitalizations and 85% efficacy against symptomatic COVID-19 in people 65 years and older.

With oncology drugs clocking a disheartening 3.4% success rate, some good news in the field is always appreciated.

No matter in which industry you are, clear communication is very important. Follow these tips for clear communications to be prepared to fit in the work environment.

First large-scale comparative effectiveness analysis of a CDK 4/6 inhibitor plus letrozole evaluating progression-free and overall survival versus letrozole alone

Passage Bio, Inc., a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, announced that management will participate in three upcoming virtual investor conferences in April

Genetron Holdings Limited, a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2020.

AGTC’s deep commitment to the patient voice drives solutions to support patient access to information and to improve the experience of patients participating in clinical trials